Thiazolidinedione derivatives (OSU-CG12) have demonstrated the ability to hinder prostate cancer progression by facilitating Sp1 degradation through modulation of Sp1 phosphorylation and ubiquitination levels (Wei et al., 2009). Here, SP1 is linked to prostate carcinoma.